Many developing countries lack the necessary infrastructure to monitor the spread of NTDs and related conditions such as malaria and tuberculosis. Some of these diseases have not been fully studied and many are not easily treated with existing medicines.
The Executive Council on Neglected Diseases coordinates efforts across the company to contribute innovative technologies, compounds for screening, and our scientific expertise. In 2012, more than 100 of AbbVie’s most experienced scientists contributed their expertise to helping solve NTDs through drug development projects, advisory boards and compound screening partner organizations. We have provided a large library of diverse chemicals to screen against many NTDs, collaborating with the following partners:
- Drugs for Neglected Diseases initiative (DNDi). AbbVie is supplying thousands of our compounds to be screened for activity against Leishmania, Chagas Disease and helminth infections. This relationship expanded in 2012 to include a four-year joint research and nonexclusive licensing agreement. The joint venture provides DNDi access to selected classes of AbbVie's proprietary molecules, identified from the above screens, and accompanying data to guide the search for improved treatments. Any products developed as a result of this partnership will be provided to endemic countries by DNDi at the lowest sustainable price to ensure the greatest patient access. Learn more at www.dndi.org.
- Gates Foundation TB Drug Accelerator (TBDA) consortium. As a founding member of TBDA, AbbVie has provided 100,000 of our compounds for screening against replicating TB. Active compounds from these screens will be shared within the consortium to speed the identification of most promising approaches to shorten and improve the quality of TB therapy. AbbVie scientists are very engaged with this partnership, providing cheminformatics support and characterizing lead compounds from other TBDA partners in addition to the above screening activities.
- TB Alliance. AbbVie scientists provide technical consulting through the TB Alliance Scientific Advisory Council, while new compounds are synthesized at AbbVie and then screened against both replicating and latent TB at the University of Illinois, Chicago. Learn more at www.tballiance.org.
- Medicines for Malaria Venture (MMV).AbbVie is working closely with MMV to support two preclinical development programs of novel antimalarials. Learn more at www.mmv.org.
- University Partnerships. We work with leading research institutions including Liverpool School of Tropical Medicine (Anti-Wolbachia Consortium, see www.a-wol.com), University of Washington, University of Sussex and University of Dundee (Drug Discovery Unit) on NTD screening and research. In addition, we provide laboratory facilities and mentor student interns under a program sponsored by Franciscan University of Steubenville (Franciscan Institute for World Health).